Research Paper
A novel cuproptosis-associated immune risk model for prediction of prognosis and response to immunotherapy in triple-negative breast cancer
Figure 7. Predicting response to immunotherapy and potential therapeutic agents. (A) The distribution of the risk score and predicted immune therapy response based on the TIDE dataset (left). The numbers of patients who might potentially response or non-response to immunotherapy in two risk groups for Fisher’s test (right). (B) Submap analysis predicted potential response to immunotherapy in low- and high-risk groups. (C) Correlation between estimated AUC values of CTRP-derived compounds and CIS score. (D) Correlation between estimated AUC values of PRISM-derived compounds and CIS score. (E) Comparison of AUC values of CTRP-derived compounds between low- and high-risk groups. (F) Comparison of AUC values of PRISM-derived compounds between low- and high-risk groups. (*P<0.05, **P< 0.01, ***P< 0.001).